Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study

INTRODUCTION: Bimekizumab treatment resulted in improved clinical outcomes in patients with moderate-to-severe plaque psoriasis in BE VIVID, a 52-week, phase 3, randomized, ustekinumab and placebo-controlled study. We present data from the BE VIVID Japan patient subpopulation. METHODS: Globally, pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Asahina, Akihiko, Okubo, Yukari, Morita, Akimichi, Tada, Yayoi, Igarashi, Atsuyuki, Langley, Richard G., Deherder, Delphine, Matano, Mizuho, Vanvoorden, Veerle, Wang, Maggie, Ohtsuki, Mamitaro, Nakagawa, Hidemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984664/
https://www.ncbi.nlm.nih.gov/pubmed/36648594
http://dx.doi.org/10.1007/s13555-022-00883-y

Ejemplares similares

Ejemplares similares